TTR and cardiomyopathy: Moreover, among 25 261 participants without known cardiomyopathy followed up over a median of 2·8 (1·2–6·4) years, AI-POCUS probabilities in the highest (vs lowest) quintile for hypertrophic cardiomyopathy and transthyretin amyloid cardiomyopathy conferred a 17% (adjusted hazard ratio 1·17, 95% CI 1·06–1·29; p=0·0022) and 32% (1·39, 1·19–1·46; p<0·0001) higher adjusted mortality risk, respectively.